kaspofungin sandoz 70 mg prašek za koncentrat za raztopino za infundiranje
sandoz d.d. - kaspofungin - prašek za koncentrat za raztopino za infundiranje - kaspofungin 70 mg / 1 viala - kaspofungin
kaspofungin sandoz 50 mg prašek za koncentrat za raztopino za infundiranje
sandoz d.d. - kaspofungin - prašek za koncentrat za raztopino za infundiranje - kaspofungin 50 mg / 1 viala - kaspofungin
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
filsuvez
amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - priprave za zdravljenje ran in razjed - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.
peros 40 mg trde gastrorezistentne kapsule
sandoz pharmaceuticals - esomeprazol - gastrorezistentna kapsula, trda - esomeprazol 40 mg / 1 kapsula - esomeprazol
peros 40 mg trde gastrorezistentne kapsule
sandoz pharmaceuticals - esomeprazol - gastrorezistentna kapsula, trda - esomeprazol 40 mg / 1 kapsula - esomeprazol
peros 20 mg trde gastrorezistentne kapsule
sandoz pharmaceuticals - esomeprazol - gastrorezistentna kapsula, trda - esomeprazol 20 mg / 1 kapsula - esomeprazol
peros 20 mg trde gastrorezistentne kapsule
sandoz pharmaceuticals - esomeprazol - gastrorezistentna kapsula, trda - esomeprazol 20 mg / 1 kapsula - esomeprazol
clopidogrel sandoz
acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - klopidogrel je indicirano pri odraslih za preprečevanje atherothrombotic dogodkov v: * bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemičnih kapi (od 7 dni do manj kot 6 mesecev) ali sedežem perifernih arterijska bolezen. za nadaljnje informacije, prosimo, preberite razdelek 5.
bendamustin sandoz 2,5 mg/ml prašek za koncentrat za raztopino za infundiranje
sandoz d.d. - bendamustinijev klorid - prašek za koncentrat za raztopino za infundiranje - bendamustinijev klorid 2,5 mg / 1 ml - bendamustin